3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinomaRecruitingPhase 1 / Phase 22026-10-08NCT07421700
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 1 / Phase 22026-09-09NCT06966453
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-05-06NCT07062965